X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - HEALTHTECHZONE.COM - IT Professionals - 08/Jul 06:00

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

Articles similaires

Sorry! Image not available at this time

Abvance Therapeutics Announces $3.9M Program Related Investment from the Helmsley Charitable Trust to Support Development of Its Novel Insulin and Glucagon Combined Formulation

healthtechzone.com - 10/Sep 13:00

Sorry! Image not available at this time

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

financialpost.com - 01/Sep 12:03

Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural...

Sorry! Image not available at this time

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

financialpost.com - 01/Sep 12:03

Dr. Scholl is a globally recognized leader in the field of ophthalmology and the coordinating principal investigator of the largest ever natural...

Sorry! Image not available at this time

MindBio advances world-first psychedelic microdosing clinical trials

themarketherald.ca - 29/Aug 14:44

MindBio Therapeutics (CSE:MBIO) announces the successful completion of its Phase 1 and 2a clinical trials on depression treatment.

Sorry! Image not available at this time

Relief Therapeutics presents PKU GOLIKE study results at SSIEM 2024

pharmabiz.com - 03/Sep 00:00

Relief Therapeutics Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare...

Sorry! Image not available at this time

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

qatarnewswire.qa - 03/Sep 12:17

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...

Sorry! Image not available at this time

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

qatarnewswire.qa - 03/Sep 12:17

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...

Sorry! Image not available at this time

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

menafocus.qa - 03/Sep 12:17

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...

Sorry! Image not available at this time

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

pressarabia.qa - 03/Sep 12:17

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...

Sorry! Image not available at this time

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

pressarabia.qa - 03/Sep 12:17

REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance...

Les derniers communiqués